shows the effect of CV-2619 on LPO production in the brain homogenate incubated for 30 min; LPO production was inhibited in a concentration- Table 1 . Reduced CV-2619 was somewhat more potent than CV-2619, and they were, respectively, 2.5-and 2-fold more potent than alpha-tocopherol.
CV-2619 has a quinone and reduced CV-2619 has a hydroquinone group. Therefore, it is likely that the reduced CV-2619 donates a hydrogen of its quinol group to the reactive free radicals of lipids which promote the initiation of LPO formation. This concept is supported by the fact that reduced CV-2619 was more potent than its oxidized form. Mellors and Tappel (12) observed that lightinduced mitochondrial lipid peroxidation was inhibited by the reduced form of ubiquinone and that the antioxidant activity of the latter was more potent than that of the former. These findings suggest that CV-2619 may be changed to its reduced form during incubation with the brain homogenate and thus exerts an inhibitory effect on LPO production.
The serum level of LPO in patients with stroke is abnormally high and a close correlation exists between the alpha-tocopherol concentration and LPO in the serum (13), and the level of LPO in the blood of strokeprone spontaneously hypertensive rats (SHRSP) with cerebral lesions is much higher than that of SHRSP without stroke or of control Wistar Kyoto rats (14). These results indicate that lipid peroxidation is closely related to cerebral vascular disorders. Demopoulos et al. (15) postulated that cerebral tissue damage in brain ischemia is due to the production of free radicals, which cause lipid peroxidation in cellular membranes.
The mitochondrial membrane especially seems to play an early role in the pathologic processes initiated by oxygen deprivation, since mitochondria contain high levels of polyunsaturated fatty acid, which is most susceptible to damage by free radicals. Therefore, compounds having antioxidant activity may prevent tissue damage by capturing the free radicals.
In conclusion, CV-2619 and its metabolite (reduced CV-2619) inhibited lipid peroxidation; this action might be involved in protecting against and improving cerebral vascular disorders. 
